BioMarin Pharmaceutical
BMRNBMRN · Stock Price
Historical price data
Overview
BioMarin Pharmaceutical is a mission-driven, revenue-generating biotech leader with a 25+ year track record of translating genetic insights into transformative medicines for rare diseases. The company's strategy centers on pursuing 'category-defining' therapies in areas of well-understood biology, leveraging core platforms in enzyme replacement therapy (ERT) and gene therapy. This approach has yielded a commercial portfolio generating significant revenue and a promising clinical pipeline, underpinned by global commercial and manufacturing infrastructure. BioMarin's financial strength and operational maturity support its ambition to sustainably deliver breakthrough science to patients worldwide.
Technology Platform
Integrated platforms in Enzyme Replacement Therapy (ERT) for lysosomal storage disorders and advanced Gene Therapy using AAV vectors for monogenic diseases.
Pipeline
121| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Naglazyme | Mucopolysaccharidosis VI | Approved | |
| saproterin dihydrochloride | Phenylketonuria | Approved | |
| Pegvaliase + Methotrexate | Phenylketonuria | Approved | |
| Kuvan® | Phenylketonuria | Approved | |
| Kuvan | Phenylketonuria (PKU) | Approved |
Funding History
2FDA Approved Drugs
7Competitors
Company Timeline
Founded in San Rafael/Novato, United States
Series A: $10.0M
IPO — $42.0M
FDA Approval: BRINEURA
FDA Approval: PALYNZIQ
FDA Approval: VOXZOGO